ClinicalTrials.gg
CompletedNCT02203812Updated Jul 27, 2016

Effect of Probiotic Lozenge on Gingivitis and Periodontitis

A Phase 3 interventional study of Probiotic Arm and Placebo Arm in Mild and Moderate Chronic Periodontitis, sponsored by CD Pharma India Pvt. Ltd.. Completed at 1 site in India. Open to participants aged 20 Years to 50 Years. Per ClinicalTrials.gov, last updated 2016-07-27.

Sponsored by CD Pharma India Pvt. Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
20 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Lymphoma, Follicular with a site in India — 4 open to participants now, 4 under way, 2 of them phase 3. Lymphoma, Follicular · India.

Enrollment
12th of 13
32 · median 213
Started
2015
with 1 other
Phase 3
8 of 15
2 open now
Registered
6th of 15
by date
Lead sponsor
1 of 15
CD Pharma India Pvt. Ltd.

Among the 15 studies in Lymphoma, Follicular with a site in India, this one is the 12th largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2015, is one of 8 in phase 3, and was the 6th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

4 of the 15 studies in Lymphoma, Follicular with a site in India are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 20 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Lymphoma, Follicular with a site in India, or all of them as a file.
02

Study summary

The oral cavity is mostly influenced by general health. The oral microbiota which is as complex as the gastro-intestinal or vaginal microbiota are considered to be difficult therapeutic targets. The effects of probiotics in different fields of health care have resulted recently in the introduction of probiotics for oral healthcare. Probiotics have been clinically proved effective in different fields of oral healthcare such as halitosis, oral candidiasis and tooth decay. They have also been inducted in the field of periodontal healthcare because of the current views on the etiology of plaque- related periodontal inflammation.

03

Conditions studied

  • Mild and Moderate Chronic Periodontitis
04

Who can participate

Ages eligible
20 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with chronic mild to moderate periodontitis.
  • Having Pocket depth > 4mm.
  • Mean loss of attachment, evaluated by measuring the distance from cement-enamel junction to the bottom of the probing pocket > 4mm

Exclusion criteria

Exclusion Criteria:

  • Patients on probiotic supplements
  • Patients who have allergy to lactose and fermented milk products
  • Smokers
  • Patients who are on antibiotic therapy or were on antibiotic therapy in the past 6 months
  • Patients with advanced periodontal and/or periapical conditions which necessitate immediate treatment
  • Patient suffering from any systemic illness
  • Patients who are deemed to be un-cooperative
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Probiotic Arm

    L. brevis CD2 Lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). Each lozenge contains at least 1 billion colony forming units of Lactobacillus brevis CD2.

    Drug: Probiotic Arm

  • Placebo comparator
    Placebo Arm

    Placebo lozenges (4 lozenges per day - 1 lozenge in the morning, 1 lozenge in the afternoon and 2 lozenges in the night). The placebo lozenge contains all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2).

    Drug: Placebo Arm

Interventions

  • Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2

  • DrugPlacebo Arm

    Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)

06

What researchers measure

Primary outcomes

  1. Improvement in Clinical Periodontal Indices

    Improvement in clinical periodontal indices, namely, Plaque Index (PI), Gingival Index (GI), Probing Pocket Depth (PPD), Bleeding on Probing (BOP)

    Time frame: 8 weeks

Secondary outcomes

  1. Improvement in Biochemical Indices

    Changes in levels of Inflammatory markers, namely, Interleukin 1β, Matrix metalloproteinases-8 (MMP), Myeloperoxidase (MPO) and Calprotectin in Gingival Crevicular Fluid (GCF)

    Time frame: 8 weeks

07

Study locations

1 site
  • Department of Periodontology, Government Dental College & Hospital
    Vijayawada, Andra Pradesh 520004, India
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015, a primary completion of Feb 2016 and a completion of May 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2014
First posted
Jul 30, 2014
Start
Jan 2015
Primary completionActual
Feb 2016
CompletionActual
May 2016
Last update
Jul 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02203812
Lead sponsor
CD Pharma India Pvt. Ltd.
Collaborators
Government Dental College and Hospital, Vijayawada, Andra Pradesh, India
Responsible party
Sponsor
First posted
Jul 30, 2014
Start date
Jan 2015
Primary completion
Feb 2016
Completion
May 2016
Last update
Jul 27, 2016

Study contacts

Surya Jyotsna Kiran Kanchumurthy, BDS
principal investigator · Government Dental College and Hospital, Vijayawada, Andhra Pradesh
Narendra Dev Jampani, MDS
study director · Government Dental College and Hospital, Vijayawada, Andhra Pradesh
Vajra Madhuri S, MDS
principal investigator · Government Dental College and Hospital, Vijayawada, Andhra Pradesh

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion